March-In Rights Likely A Slow Trot at Best

March-In Rights Likely A Slow Trot at Best

Published On: 02/08/2022Tags: Agencies, Biopharma

Xtandi’s High US Price Reinvigorates Government IP Rights Debate

Access memo here